BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 28562168)

  • 1. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
    Liang Q; Li H; Xie X; Qu F; Li X; Chen J
    Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial.
    Chen M; Li H; Li XY; Lu FM; Ni ZH; Xu FF; Li XW; Chen JH; Wang HY;
    Am J Med Sci; 2010 Mar; 339(3):233-8. PubMed ID: 20220333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome.
    Yuan H; Liu N; Sun GD; Jia Y; Luo P; Miao LN
    Pharmacology; 2013; 91(5-6):259-66. PubMed ID: 23652322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
    J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids.
    He L; Peng Y; Liu H; Liu Y; Yuan S; Liu F; Yang D; Liu H; Chen X; Shao J; Fu M
    J Nephrol; 2013; 26(3):564-71. PubMed ID: 22956434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy.
    Shang SL; Cai GY; Duan SW; Li P; Li QG; Chen XM
    BMC Nephrol; 2018 Jul; 19(1):182. PubMed ID: 30021637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis.
    Li YC; Huang J; Li X; Zhao SM
    Nefrologia (Engl Ed); 2019; 39(3):269-276. PubMed ID: 30755327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early initiation of immunosuppressive treatment in membranous nephropathy patients.
    Chan CK; Lai TS; Chen PM; Chou YH; Wu CF; Chiu YL; Chiang WC; Chen YM; Chu TS; Wu KD
    J Formos Med Assoc; 2017 Apr; 116(4):266-275. PubMed ID: 28202222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
    Peng L; Wei SY; Li LT; He YX; Li B
    J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria.
    Matsumoto Y; Shimada Y; Nojima Y; Moriki T
    Ren Fail; 2013 Aug; 35(7):936-41. PubMed ID: 23815417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
    Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
    Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy.
    Cui W; Lu X; Min X; Liu M; Guan S; Wang Y; Luo M; Li W; Li Q; Dong W; Miao L; Luo P
    Braz J Med Biol Res; 2017 Mar; 50(4):e5976. PubMed ID: 28355356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
    Wu B; Mao J; Shen H; Fu H; Wang J; Liu A; Gu W; Shu Q; Du L
    Nephrology (Carlton); 2015 Jan; 20(1):18-24. PubMed ID: 25312783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.
    Goumenos DS; Kalliakmani P; Tsakas S; Sotsiou F; Vlachojannis JG
    Clin Nephrol; 2004 Jan; 61(1):17-24. PubMed ID: 14964453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial.
    Xu J; Zhang W; Xu Y; Shen P; Ren H; Wang W; Li X; Pan X; Chen N
    Contrib Nephrol; 2013; 181():152-62. PubMed ID: 23689577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
    Yang S; Xie L; Xue W; Yin A; Lu W
    Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy.
    Ramachandran R; Kumar V; Jha V
    Kidney Int; 2016 Jun; 89(6):1401-2. PubMed ID: 27181781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.